All In Biotech

Drug Trial Radar · NCT05137054

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

317

Planned (sponsor's estimate)

Start

Aug 17, 2022

Primary completion

Mar 25, 2028

Study completion Mar 24, 2032

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies). This study is the first time linvoseltamab will be combined with other cancer therapies. The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma * What side effects may happen from taking linvoseltamab together with another cancer treatment * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

Conditions

  • Multiple Myeloma

Interventions

  • LinvoseltamabDrug

    Administered per the protocol

  • DaratumumabDrug

    Administered per the protocol

  • CarfilzomibDrug

    Administered per the protocol

  • LenalidomideDrug

    Administered per the protocol

  • BortezomibDrug

    Administered per the protocol

  • PomalidomideDrug

    Administered per the protocol

  • IsatuximabDrug

    Administered per the protocol

  • FianlimabDrug

    Administered per the protocol

  • CemiplimabDrug

    Administered per the protocol

  • NirogacestatDrug

    Administered per the protocol

  • CevostamabDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation periodTime frame: Up to 28 Days
  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 5 Years
  3. Severity of TEAEsTime frame: Up to 5 Years
  4. Incidence of Serious Adverse Events (SAEs)Time frame: Up to 5 Years
  5. Severity of SAEsTime frame: Up to 5 Years
  6. Incidence of Adverse Events of Special Interest (AESIs)Time frame: Up to 5 Years
  7. Severity of AESIsTime frame: Up to 5 Years
  8. Incidence of laboratory abnormalitiesTime frame: Up to 5 Years

Locations

42 sites in 5 countries. Site status is shown where the registry gives one.

  • Scripps Clinic Torrey Pines

    La Jolla, California · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • Indiana University Health Simon Cancer Center

    Indianapolis, Indiana · Recruiting

  • Dana Farber/Harvard Cancer Center

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Weill Cornell Medicine/New York Presbyterian Hospital

    New York, New York · Recruiting

  • New York Presbyterian Hospital Columbia University Medical Center

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Recruiting

  • The Ohio State University James Cancer Hospital

    Columbus, Ohio · Recruiting

  • University of Texas Southwestern

    Dallas, Texas · Recruiting

  • VA Puget Sound Health Care System

    Seattle, Washington · Recruiting

  • Centre Hospitalier Universitaire Angers

    Angers, France · Recruiting

  • CHU Montpellier - Departement D'Hematologie

    Montpellier, France · Recruiting

  • Saint Antoine Hospital

    Paris, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Hospital Henri Mondor

    Créteil, Île-de-France Region, France · Recruiting

  • Saint Louis Hospital

    Paris, Île-de-France Region, France · Recruiting

  • Hopital Necker

    Paris, Île-de-France Region, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Poitiers

    Poitiers, New Aquitaine, France · Recruiting

  • CHU de Lille - Rue Michel Polonovski

    Lille, Nord, France · Recruiting

  • Nantes University Hospital

    Nantes, Pays de la Loire Region, France · Recruiting

  • General Hospital of Athens Alexandra

    Athens, Greece · Recruiting

  • Evangelismos General Hospital

    Athens, Attica, Greece · Recruiting

  • Rambam Health Care Campus

    Haifa, Israel · Recruiting

  • Hadassah Medical Center

    Jerusalem, Israel · Recruiting

  • Sheba Medical Center

    Ramat Gan, Central District, Israel · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,

    Barcelona, Spain · Recruiting

  • Universitaru Hospital La Princesa

    Madrid, Spain · Recruiting

  • Clinica Universidad de Navarra - Madrid

    Madrid, Spain · Recruiting

  • Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria

    Madrid, Spain · Recruiting

  • University Hospital and Research Institute

    Madrid, Spain · Recruiting

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain · Recruiting

  • University Hospital of Salamanca

    Salamanca, Spain · Recruiting

  • Hospital Clinico Universitario de Santiago

    Santiago de Compostela, A Coruna, Spain · Recruiting

  • Hospital Germans Trias i Pujol

    Badalona, Barcelona, Spain · Recruiting

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, Spain · Recruiting

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.